Figure 1
Figure 2
Figure 3
Figure 4
Association between the positive index and clinicopathological parameters_
| LMP-1, E-Cadherin | |||
|---|---|---|---|
| PI = 0, n (%) | PI = 0.5, n (%) | PI = 1.0, n (%) | |
| Gender: | |||
| males | 14 (15.06) | 11 (11.83) | 43 (46.24) |
| females | 1 (1.08) | 6 (6.45) | 18 (19.35) |
| p Value | 0.14 | ||
| Age (years): | |||
| <20 | 0 (0.00) | 0 (0.00) | 1 (1.08) |
| 20 to 40 | 3 (3.23) | 5 (5.38) | 9 (9.68) |
| 40 to 60 | 6 (6.45) | 6 (6.45) | 31 (33.33) |
| 60 to 80 | 5 (5.38) | 6 (6.45) | 20 (21.51) |
| >80 | 1 (1.08) | 0 (0.00) | 0 (0.00) |
| p Value | 0.42 | ||
| Histological typea: | |||
| type 1 | 0 (0.00) | 1 (1.08) | 3 (3.23) |
| type 2 | 7 (7.53) | 5 (5.38) | 14 (15.05) |
| type 3 | 8 (8.60) | 11 (11.83) | 44 (47.31) |
| p Value | 0.42 | ||
| Stage: | |||
| I | 0 (0.00) | 0 (0.00) | 0 (0.00) |
| II | 4 (4.30) | 10 (10.75) | 19 (20.43) |
| III | 5 (5.38) | 3 (3.23) | 7 (7.53) |
| IV | 6 (6.45) | 4 (4.30) | 35 (37.63) |
| p Value | 0.04 | ||
The primer sequences used_
| For evaluation of LMP-1 expression | For evaluation of LMP-1 expression |
|---|---|
| Primers [Refs.] | Sequences (5’>3’) |
| LMP-1-F [18] | CAG TCA GGC AAG CCT ATG A |
| LMP-1-R [18] | CTG GTT CCG GTG GAG ATG A |
| GAPDH-F [19] | TGC CTC CTG CAC CAC CAA CT |
| GAPDH-R [19] | CGC CTG CTT CAC CAC CTT C |
Association between the expression of LMP-1, methylation of E-cadherin and clinicopathological parameters_
| LMP-1 | E-Cadherin | |||
|---|---|---|---|---|
| Positive, n (%) | Negative, n (%) | Methylated, n (%) | Unmethylated, n (%) | |
| Gender: | ||||
| males | 51 (54.83) | 17 (18.28) | 46 (49.46) | 22 (23.66) |
| females | 20 (21.51) | 5 (5.38) | 22 (23.66) | 3 (3.23) |
| p Value | 0.06 | 0.05 | ||
| Age (years):<20 | 1 (1.08) | 0 (0.00) | 1 (1.08) | 0 (0.00) |
| 20 to 40 | 11 (11.83) | 6 (6.45) | 12 (12.90) | 5 (5.38) |
| 40 to 60 | 36 (38.71) | 7 (7.53) | 32 (34.41) | 11 (11.83) |
| 60 to 80 | 23 (24.73) | 8 (8.60) | 23 (24.73) | 8 (8.60) |
| >80 | 0 (0.00) | 1 (1.08) | 0 (0.00) | 1 (1.08) |
| p Value | 0.19 | 0.52 | ||
| Histological typea: | ||||
| type 1 | 3 (3.23) | 1 (0.00) | 4 (4.30) | 0 (0.00) |
| type 2 | 17 (18.28) | 9 (9.68) | 16 (17.20) | 10 (10.75) |
| type 3 | 51 (54.83) | 12 (12.90) | 48 (51.61) | 15 (16.13) |
| p Value | 0.29 | 0.16 | ||
| Stage: | ||||
| I | 0 (0.00) | 0 (0.00) | 0 (0.00) | 0 (0.00) |
| II | 26 (27.96) | 7 (7.53) | 22 (23.66) | 11 (11.83) |
| III | 8 (8.60) | 7 (7.53) | 9 (9.68) | 6 (6.45) |
| IV | 37 (39.78) | 8 (8.60) | 37 (39.78) | 8 (8.60) |
| p Value | 0.07 | 0.14 | ||
Characteristics of enrolled clinical nasopharyngeal carcinoma NPC samples_
| n = 93 | n (%) |
|---|---|
| Gender: | |
| males | 68 (73.12) |
| females | 25 (26.88) |
| Age (years: | |
| <20 | 1 (1.08) |
| 20 to 40 | 17 (18.28) |
| 40 to 60 | 43 (46.23) |
| 60 to 80 | 31 (33.33) |
| >80 | 1 (1.08) |
| Histological typea: | |
| type 1 | 4 (4.30) |
| type 2 | 26 (27.96) |
| type 3 | 63 (67.74) |
| Stage: | |
| I | 0 (0.00) |
| II | 33 (35.48) |
| III | 15 (16.13) |
| IV | 45 (48.39) |
Statistical analysis of association between LMP-1 expression and methylation of E-cadherin in nasopharyngeal carcinoma samples_
| LMP-1 Expression | |||
|---|---|---|---|
| Positive, n (%) | Negative, n (%) | p Value | |
| E-cadherin methylation: | |||
| positive, n (%) | 61 (65.59) | 7 (7.53) | <0.0001 |
| negative, n (%) | 10 (10.75) | 15 (16.13) | |